KURA NASDAQ
Kura Oncology, Inc.
1W: -0.8%
1M: -6.7%
3M: +10.9%
YTD: -4.3%
1Y: +2.1%
3Y: +19.7%
5Y: -44.2%
$9.90
+0.28 (+2.91%)
After Hours: $10.07 (+0.17, +1.72%)
Weekly Expected Move ±6.2%
$8
$9
$10
$10
$11
Credit Risk of going bust: lower than 73% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $855.8M.
Distance to default 8.14 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 58.1%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $855.8M.
Distance to default 8.14 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 58.1%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$2.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$880.7M
52W Range7.358-13.9
Volume1,709,675
Avg Volume1,776,945
Beta0.38
Dividend—
Analyst Ratings
Company Info
CEOTroy Wilson
Employees260
SectorHealthcare
IndustryBiotechnology
IPO Date2015-09-16
Websitekuraoncology.com
4930 Directors Place
San Diego, CA 92121
US
San Diego, CA 92121
US
858 500 8800
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The companyâs first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest News
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Average Price Target of $25.69
Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 28,802 Shares of Stock
Kura Oncology (NASDAQ:KURA) Insider Mollie Leoni Sells 12,448 Shares of Stock
Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 17,020 Shares of Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| FORD KATHLEEN | S-Sale | 3,668 | $10.75 | 2026-09-29 |
| Leoni Mollie | S-Sale | 28,802 | $10.75 | 2026-09-29 |
| Powl Brian T. | S-Sale | 15,430 | $10.75 | 2026-09-29 |
| Bair Teresa Brophy | S-Sale | 8,442 | $10.50 | 2026-09-28 |
| FORD KATHLEEN | S-Sale | 6,906 | $10.50 | 2026-09-28 |